BR0317857A - Tratamento de anorexia nervosa (an) e bulimia - Google Patents

Tratamento de anorexia nervosa (an) e bulimia

Info

Publication number
BR0317857A
BR0317857A BR0317857-9A BR0317857A BR0317857A BR 0317857 A BR0317857 A BR 0317857A BR 0317857 A BR0317857 A BR 0317857A BR 0317857 A BR0317857 A BR 0317857A
Authority
BR
Brazil
Prior art keywords
bulimia
treatment
anorexia nervosa
anorexia
nervosa
Prior art date
Application number
BR0317857-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Frederick Horro David
Agnes Ayton
Original Assignee
Amarin Neuroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0317857(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amarin Neuroscience Ltd filed Critical Amarin Neuroscience Ltd
Publication of BR0317857A publication Critical patent/BR0317857A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
BR0317857-9A 2002-09-16 2003-09-16 Tratamento de anorexia nervosa (an) e bulimia BR0317857A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0221480.7A GB0221480D0 (en) 2002-09-16 2002-09-16 Treatment of anorexia nervosa (AN) and bulimia
PCT/GB2003/003985 WO2004024136A1 (en) 2002-09-16 2003-09-16 Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia

Publications (1)

Publication Number Publication Date
BR0317857A true BR0317857A (pt) 2005-12-06

Family

ID=9944164

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317857-9A BR0317857A (pt) 2002-09-16 2003-09-16 Tratamento de anorexia nervosa (an) e bulimia

Country Status (20)

Country Link
US (1) US20060135608A1 (enExample)
EP (1) EP1556028A1 (enExample)
JP (1) JP2006503031A (enExample)
KR (1) KR20050042823A (enExample)
CN (1) CN1694694A (enExample)
AU (1) AU2003269138A1 (enExample)
BR (1) BR0317857A (enExample)
CA (1) CA2499142A1 (enExample)
GB (1) GB0221480D0 (enExample)
HR (1) HRP20050245A2 (enExample)
IS (1) IS7744A (enExample)
MX (1) MXPA05002943A (enExample)
NO (1) NO20051847L (enExample)
NZ (1) NZ538793A (enExample)
PL (1) PL375726A1 (enExample)
RS (1) RS20050226A (enExample)
RU (1) RU2330653C2 (enExample)
TW (1) TW200410682A (enExample)
WO (1) WO2004024136A1 (enExample)
ZA (1) ZA200502161B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
EP1683519A4 (en) * 2003-11-14 2009-04-01 Mochida Pharm Co Ltd PREVENTIVE / THERAPEUTIC AGENT FOR TREATING SPEECH DISORDERS
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および/又はうつ症状の改善作用を有する組成物
WO2008081989A1 (ja) 2006-12-28 2008-07-10 Suntory Holdings Limited 神経再生剤
CA2672513C (en) 2007-02-15 2010-05-25 Centre De Recherche Sur Les Biotechnologies Marines Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US8816110B2 (en) 2007-02-15 2014-08-26 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
EP2136844B1 (en) 2007-03-20 2018-10-31 SCF Pharma Inc. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CN108096209A (zh) * 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
CA2825037A1 (en) * 2011-02-11 2012-08-16 E.I. Du Pont De Nemours And Company An eicosapentaenoic acid concentrate
US9447020B2 (en) 2013-10-31 2016-09-20 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
RU2545988C1 (ru) * 2013-11-12 2015-04-10 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы Способ лечения хронического запора и функциональной анорексии
CN111971041A (zh) 2018-02-07 2020-11-20 Scf制药股份有限公司 多不饱和脂肪酸单甘油酯、组合物、方法及其用途
US20210130897A1 (en) * 2018-04-16 2021-05-06 Quadrant Biosciences Inc. Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status
CN112384212A (zh) 2018-05-03 2021-02-19 Scf制药股份有限公司 多不饱和脂肪酸单甘油酯、其组合物、方法和用途
CN109276262B (zh) * 2018-07-30 2021-01-26 中国科学院心理研究所 一种用于筛选高危进食障碍的检测系统
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
EP4125836A1 (en) * 2020-03-27 2023-02-08 Homeostasis Therapeutics, Limited Method of treatment for anorexia nervosa, bulimia and related clinical syndromes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes

Also Published As

Publication number Publication date
GB0221480D0 (en) 2002-10-23
TW200410682A (en) 2004-07-01
ZA200502161B (en) 2005-09-15
EP1556028A1 (en) 2005-07-27
MXPA05002943A (es) 2005-06-03
JP2006503031A (ja) 2006-01-26
NO20051847L (no) 2005-04-15
HRP20050245A2 (en) 2005-10-31
CA2499142A1 (en) 2004-03-25
RU2005107416A (ru) 2006-01-20
NZ538793A (en) 2007-05-31
RU2330653C2 (ru) 2008-08-10
CN1694694A (zh) 2005-11-09
RS20050226A (sr) 2007-09-21
US20060135608A1 (en) 2006-06-22
IS7744A (is) 2005-03-15
PL375726A1 (en) 2005-12-12
AU2003269138A1 (en) 2004-04-30
KR20050042823A (ko) 2005-05-10
WO2004024136A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
ZA200309887B (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
EP2500438A3 (en) Novel compositions and methods for the treatment of psoriasis
BRPI0417543A (pt) quinolinas úteis no tratamento de doença cardiovascular
ATE432072T1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
MXPA04003796A (es) Tioacetamidas sustituidas.
UA83691C2 (ru) Применение замещенных 2-аминотетралинов для упреждающего лечения болезни паркинсона
NO20051847L (no) Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi.
EP1499328A4 (en) METHOD FOR TREATING NEKROTIZING ENTEROCOLITIS
BRPI0506449A (pt) utilização de espilantol e processo de tratamento cosmético de rugas
DE60207490D1 (de) Verfahren zur Herstellung von (Meth)Acrylsäureanhydrid
BR0111188A (pt) Inibidores de adesão de célula mediada por alfal beta2
DE69424009D1 (de) Verwendung von (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidinacetamid zur Herstellung eines Medikaments zur Behandlung von Angst
UY27841A1 (es) Amidas de ácidos 2-heteroarilcarboxílicos
ATE297222T1 (de) Zusammensetzungen enthaltend eine niedrige konzentration an peroxide zur behandlung von vaginitis
ES2083396T3 (es) Acidos fenilalcan(en)oicos.
CY1113871T1 (el) Διαδικασια παρασκευης γκαμπαπεντινης
SE0200844D0 (sv) Chemical compounds
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
BR0316549A (pt) ésteres de ácido carbamìnico com efeito anticolinérgico
BRPI0408899A (pt) compostos benzo[1,2,5]tiadiazol
ATE345121T1 (de) Verwendung von konjugierter linolsäure zur behandlung der erkältung

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.